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ToxicityMedicinal plant use plays an important role in the healthcare of many South Africans. Furthermore, in orthodox
medicine, conventional antimicrobial agents are amongst themost commonly prescribed groups of drugs. There-
fore, due to the prevalence of use of these two forms of healthcare, there is a high probability for their concurrent
use. Thus, the aim of this study was to evaluate the interactive antimicrobial and toxicity proﬁles of six Southern
African medicinal plants (Agathosma betulina, Aloe ferox, Artemisia afra, Lippia javanica, Pelargonium sidoides and
Sutherlandia frutescens) when combined with seven conventional antimicrobials (ciproﬂoxacin, erythromycin,
gentamicin, penicillin G, tetracycline, amphotericin B and nystatin). Antimicrobial activity was assessed using
the minimum inhibitory concentration (MIC) assay against a range of pathogens and interactions were further
classiﬁed using the sum of the fractional inhibitory concentration (∑FIC). Notable synergistic or antagonistic in-
teractionswere studied at various ratios (isobolograms). The toxicity of the individual samples, as well as the no-
table combinations, was assessed using the brine-shrimp lethality assay (BSLA) and the 3-(4,5 dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on the HEK-293 human cell line. Of the 420 antimicrobial:
plant combinations studied, 14.29% showed synergistic interactions, 7.56% antagonistic, 35.71% additive and
42.44% indifferent interactions. Some notable synergistic interactions (ciproﬂoxacin with A. betulina and
S. frutescens against Escherichia coli) and antagonistic interactions (ciproﬂoxacin with A. afra organic extract
against Escherichia coli) were identiﬁed. None of the notable combinations were found to show toxicity in the
BSLA or MTT assay. In conclusion, the majority of combinations were found to have no notable interaction, alle-
viating some concern related to the concurrent use of these two forms of healthcare.
© 2014 SAAB. Published by Elsevier B.V. All rights reserved.1. Introduction
Medicinal plants have been used for centuries as a source of medi-
cine. The global importance of medicinal plants can be illustrated by
the numerous conventional drugs that have been derived from plants
and are currently used in clinical practice. Some examples of these
drugs are quinine, atropine, opioids and taxol. In Africa, traditionally
used medicinal plants play a vital role in the cultural heritage of the
local people, with an estimated 60% of the population consulting tradi-
tional healers (Chinyama, 2009; Van Wyk et al., 2009). Approximately
3000 plants are used in traditional healing practices in South Africa by
an estimated 200,000 traditional healers (VanWyk et al., 2009). Popular
Southern African medicinal plants, such as Agathosma betulina,
Aloe ferox, Artemisia afra, Lippia javanica, Pelargonium sidoides and
Sutherlandia frutescens, have been studied for their medicinal, antimi-
crobial and toxic properties (Table 1).7 11 6424355.
Vuuren).
hts reserved.Interest in medicinal plant research has escalated, with the aim of
identifying alternative antimicrobial therapies to overcome resistance
(Aiyegoro and Okoh, 2009). There is, however, general consensus
amongst the various studies, that plant derived antimicrobials possess
a lower potency than conventional antimicrobials (Van Vuuren and
Viljoen, 2011). Furthermore, antimicrobial resistance against conven-
tional antimicrobials has been on the rise and has become a major pub-
lic health concern. This has propelled research in the direction of
combination therapies for enhanced efﬁcacy. Many researchers have
studied antimicrobial interactions between natural products, as well
as combinations of natural products with conventional therapies.
Websites now exist that are dedicated to herb–drug interactions
(www.prescribeguide.com). Combinations of agents with antimicrobial
properties that have already been investigated include combinations
of various essential oils (Van Vuuren and Viljoen, 2006; Suliman et al.,
2010) and conventional antimicrobial combinations with non-
conventional antibiotics, such as anaesthetics (Gunics et al., 2000). Sev-
eral studies investigating natural product combinations with conven-
tional antimicrobials have already been conducted (Betoni et al., 2006;
Rosato et al., 2007, 2008, 2009; D'Arrigo et al., 2010; Jarrar et al., 2010;
Table 1
Medicinal plants investigated, with their traditional uses, evidence of toxicity and antimicrobial activity.
Plant, family and common names Part used/mode of administration Traditional medicinal uses Known toxicity Known antimicrobial activitya References
Agathosma betulina (Berg.) Pillans,
Rutaceae, buchu (Khoi, English),
boegoe (Afrikaans), ibuchu (Xhosa).
Decoction or alcoholic tincture
from leaves for gastrointestinal
complaints. Infusions prepared
from leaves ingested for kidney
troubles. Buchu vinegar applied
topically.
Kidney and urinary tract
infections (UTI's), wounds, boils,
rash, burns, gastrointestinal
complaints, antibiotic protection
of corpses.
No toxic effect on kidney cells (IC50 N 100 μg/ml).
Allergic reactions have occurred.
Very weak activity against
E. coli, S. aureus, B. cereus, E.
faecalis, K. pneumoniae,
P. aeruginosa and
C. neoformans.
Watt and Breyer-Brandwijk (1962),
Hutchings et al. (1996), Lis-Balchin et al.
(2001), Moolla (2005), Moolla and Viljoen
(2008), Van Wyk et al. (2009), Suliman
et al. (2010), Van Wyk (2011).
Aloe feroxMill., Asphodelaceae,
bitteraalwyn, Kaapse aalwyn
(Afrikaans), bitter aloe (English),
umhlaba (Xhosa, Zulu, Sotho).
Fresh juice from leaves or
decoctions and powders from
leaves or roots applied topically or
sniffed.
Ophthalmic inﬂammation,
sexually transmitted infections,
wounds, burns, sinusitis,
conjunctivitis.
Joint weakness, partial paralysis, effects similar to
curare poisoning, overdoses lead to nephritis,
gastritis and pelvic congestion. No cytotoxicity at
low doses.
Moderate to very weak activity
against C. albicans, Neisseria
gonorrhoeae and Herpes simplex.
Watt and Breyer-Brandwijk, 1962,
Hutchings et al. (1996), Kambizi et al.
(2007), Kambizi and Afolayan (2008), Van
Wyk et al. (2009), Van Wyk (2011),
Wintola et al. (2011).
Artemisia afra Jacq. ex. Willd.,
Asteraceae, umhlonyane (Xhosa,
Zulu), lengana (Sotho, Tswana), als,
alsem, wildeals (Afrikaans), african
wormwood (English).
Infusion or decoction from leaves
or roots for ingestion, poultice of
leaves for topical application.
Fumes from boiled leaves for
inhalation.
Respiratory infections (coughs,
colds, pneumonia, croup,
whooping cough),
gastrointestinal complaints,
malaria, intestinal worms, boils.
Pulmonary oedema, haemorrhagic nephritis,
degenerative liver changes, central nervous
system effects due to thujone (hallucinations,
confusion).
Moderate to very weak activity
against B. cereus, E. faecalis,
S. aureus, E. coli, K. pneumoniae,
C. albicans P. aeruginosa, and
C. neoformans.
Watt and Breyer-Brandwijk (1962),
Hutchings et al. (1996), Huffman et al.
(2002), Van Vuuren and Viljoen (2006),
Mukinda and Syce (2007), Van Wyk et al.
(2009), Suliman et al. (2010), Van Wyk
(2011).
Lippia javanica (Burm. F.) Spreng.,
Verbenaceae, musukudu,
bokhukhwane (Tswana),
inzinziniba (Xhosa), umsuzwane
(Zulu), mumara (Shona), fever tea
(English), koorsbossie (Afrikaans).
Weak infusions prepared from
leaves, twigs and roots made with
milk or water, smoke inhalation or
the direct application of leaves.
Respiratory infections (coughs,
colds, bronchitis, inﬂuenza), skin
infections, gastrointestinal
complaints, malaria, measles,
rashes, disinfecting anthrax-
infected meat.
Photosensitivity but no other evidence of toxicity. Moderate to very weak activity
against S. aureus, B. cereus,
E. faecalis, E. coli,
K. pneumoniae, C. albicans,
P. aeruginosa and
C. neoformans.
Watt and Breyer-Brandwijk (1962),
Hutchings et al. (1996), Huffman et al.
(2002), Van Vuuren and Viljoen (2006),
Van Wyk et al. (2009), Van Wyk (2011).
Pelargonium sidoides DC., Geraniaceae,
umckaloabo (Zulu), silverleaf
geranium (English), kalwerbossie
(Afrikaans).
Root decoction or infusion made
with milk or water for ingestion
and topical application. Root can
be chewed or powdered for
ingestion with food.
Respiratory infections
(bronchitis, sinusitis, inﬂuenza,
pneumonia), sexually
transmitted infections,
gastrointestinal complaints,
wounds.
Hepatotoxicity reports caused by P. sidoides ruled
out.
Moderate to very weak activity
againstMycobacterium
tuberculosis, S. aureus,
S. pneumoniae, E. coli,
K. pneumoniae, P. aeruginosa
and Haemophilus inﬂuenzae.
Watt and Breyer-Brandwijk (1962),
Hutchings et al. (1996),Mukinda and Syce
(2007), Van Wyk et al. (2009), Kolodziej
(2011), Van Wyk (2011), Teschke et al.
(2012).
Sutherlandia frutescens (L.) R. Br.,
Fabaceae, kankerbos (Afrikaans),
cancer bush (English).
Strong decoctions or alcoholic
tinctures made from leaves for
internal or external use.
Respiratory infections (chronic
bronchitis, colds, inﬂuenza),
UTI's, wounds, gastrointestinal
complaints, internal cancer and
septicaemia.
No toxic effects on liver, kidney, muscles, lungs,
bone and biochemical parameters found in mice
given enormous doses. Considered safe due to
long history of use in South Africa without reports
of any toxicity. No toxic effects in healthy adults.
Moderate to very weak activity
against S. aureus and other
Staphylococcal spp., E. faecalis
and E. coli.
Watt and Breyer-Brandwijk (1962),
Hutchings et al. (1996), Seier et al.
(2002), Katerere and Eloff (2005), Fu et al.
(2008), Van Wyk et al. (2009), Van Wyk
(2011).
a Moderate antimicrobial activity = MIC of 1.00–3.00 mg/ml; very weak antimicrobial activity = MIC of ≥8.00 mg/ml.
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combinations with common herbs such as Rosmarinus ofﬁcinalis,
Origanum vulgare, Thymus vulgaris, Mentha piperita and Melaleuca
alternifolia. Some combination studies of natural products and conven-
tional antimicrobials have also focused on the isolation of phytochemi-
cals, such as phenols, tannins and ﬂavonoids and evaluating these
effects on antimicrobials, with many synergistic interactions having
been identiﬁed (Sibanda and Okoh, 2007; Hemaiswarya et al., 2008;
Jayaraman et al., 2010; Palaniappan and Holley, 2010). Various plants
have been found to be synergistic enhancers for conventional antimi-
crobials, even if the plants do not possess antimicrobial activity them-
selves (Aiyegoro and Okoh, 2009). Adwan et al. (2010), as well as Van
Vuuren and Viljoen (2011), highlight that the potentiating effect of
plants on conventional antimicrobials has been neglected and this as-
pect requires further investigation.
Not only is it important to investigate these combinations to identify
possible alternatives to overcome resistance, but combination studies
also provide valuable information for use in the clinical setting, where
natural product–drug interactions can occur. Many people in Southern
Africa use both traditional and conventional medications concurrently
(VanWyk et al., 2009) without knowledge of the potential interactions
which may occur. The lack of knowledge of interactions between natu-
ral products and conventional drugs, as well as the lack of reporting of
natural product or traditional medicinal use to healthcare professionals
can pose a serious risk to patient safety (Butterweck and Derendoff,
2012; Vieira and Huang, 2012). It has been acknowledged that even in
some of the ﬁnest hospitals, traditional medicine is found to be used
by patients in conjunction with conventional therapies [personal com-
munication, Dr. Motlalepula Matsabisa, Director IKS Health Unit, Medi-
cal Research Council (MRC)]. The practice of combining traditional or
natural products with conventional medicine has been found prevalent
not only in Southern Africa, but also globally. In a study conducted in
Western countries in 2005, 12.1–18.6% of the population indicated
herbal drug use concomitantly with prescription drugs reaching 16%
(Tindle et al., 2005; Singh and Levine, 2006). In Canada, 9–23.2% of the
population indicated herbal drug use, with 5.3% conﬁrming concurrent
usewith prescription drugs (Singh and Levine, 2006). A national survey
performed in the United States of America, indicated that 72% of
patients using herbal remedies were found to be additionally using
prescription drugs. Furthermore, 84% of patients reported using over-
the-counter medication in combination with natural products. Some
patients preferentially combined these two forms of healthcare, with
the belief that there would be an enhanced effect (Maizes and Dog,
2010).
There have been many instances where natural products have
been used concurrently with conventional medicine and severe re-
actions have resulted. Well characterised interactions have been
summarised by Vickers et al. (2001), where it was reported that sev-
eral traditional/conventional medicine interactions are not yet well
deﬁned and it has been recommended that if patients are taking con-
ventional medication, that traditional remedies should be used with
caution. There is a misconception amongst many people that natural
products are safe. Natural products still have the potential for severe
interactions and many are not devoid of toxicity (Hermann and Von
Richter, 2012; Markowitz and Zhu, 2012). With most of the studies
to date focusing only on testing antimicrobial activity of the
combinations, the identiﬁcation of possible toxic effects of these
combinations have been neglected. Many studies have, however, ac-
knowledged the need for toxicological screening, not only of the in-
dividual plants, but also on combinations (Fennell et al., 2004; Adwan
et al., 2009). Some medicinal plants at higher than therapeutic doses
are toxic, as demonstrated in a reviewby Fennell et al. (2004). However,
this toxicity is usually only evidentwhen themedication is consumed in
large quantities or for prolonged periods. Existing evidence of toxicity of
the plants investigated in this current study has been summarised in
Table 1.In spite of the extensive studies that have already been reported on
the interactions between natural products and conventional antimicro-
bials, no studies could be found that provides information of possible in-
teractions of commercially relevant, Southern African medicinal plants
in combination with conventional antimicrobials. This cannot be ig-
nored, hence a comprehensive investigation of these interactions is
warranted. Interactive proﬁles could have a considerable effect on con-
ventional treatment regimens, particularly since most patients do not
report traditional medicine use to healthcare providers. Therefore, the
purpose of this study was to evaluate the interactive antimicrobial and
toxicity proﬁles, when six Southern Africanmedicinal plants were com-
bined with seven conventional antimicrobial agents. The plants used in
this investigation (Table 1) are all included in the 350 species classiﬁed
as themost commonly used and tradedmedicinal plants in South Africa
(VanWyk et al., 2009) and are also in the top 16 plants classiﬁed asmost
commercially relevant in a review by Van Wyk (2011).
2. Material and methods
2.1. Sourcing and preparation of plant samples
A. betulina (batch VV 01/13/02/12) was purchased from the com-
mercial trader, S. Chicken Naturals, Cape Town. A. ferox (voucher SVV-
173) and A. afra (voucher SVV-172) were collected from the Walter
Sisulu National Botanical Gardens, Gauteng. These plants were identi-
ﬁed andharvested under the guidance of AndrewHankey, Associate Cu-
rator, South African National Biodiversity Institute. L. javanica (voucher
SVV-174) was identiﬁed and collected by Assoc. Prof. S.F. Van Vuuren
from the wild population in Fairlands, Johannesburg. P. sidoides (batch
0212105) and S. frutescens (batch 0312010) were purchased from
Parceval (Pty) Ltd. Pharmaceuticals, Cape Town. Certiﬁcates of analysis
were received from Parceval (Pty) Ltd. Pharmaceuticals for these two
plants, providing proof of purity. All plant harvesting occurred during
the warm summer months and the plant material was received at the
University of the Witwatersrand in March 2012. The plant parts
analysed in this study were selected to be most closely related to the
parts traditionally used.
Plant material was left to dry at room temperature for approximate-
ly seven days until completely dry, after which, it was ground into a ﬁne
powder using the high speed Fritsch Pulverisette grinder (Labotec). For
organic extracts, the dried, macerated plant material was submerged in
a mixture of dichloromethane and methanol (1:1) for 24 h at 37 °C in a
shaker/incubator (Labcon). Thereafter, the liquid was ﬁltered and the
ﬁltrate left in open glass bottles, under a fume hood, for the complete
evaporation of solvent, leaving behind the solid extract. Aqueous ex-
tracts were prepared by submerging the macerated plant material in
sterile distilled water for 24 h at 25 °C in a shaker/incubator. The liquid
was then ﬁltered and the ﬁltrate stored at−80 °C before lyophilisation
(Virtis). Aqueous extracts were left under ultra-violet light overnight to
ensure the elimination of any microbial contamination. Extracts were
stored in sealed sterile bottles, at room temperature and protected
from light, until further analysis.
Essential oils from the aromatic plants (A. afra, A. betulina and
L. javanica) were hydro-distilled, using a Clevenger-type apparatus.
Round bottom ﬂasks, with a 5 l capacity, were packed tightly with
fresh, aerial plant material and approximately 800 ml of distilled
water was added to each ﬂask. The condensed essential oils were col-
lected in amber, glass vials (Macherey-Nagel) to prevent evaporation,
and stored at 4 °C until further analysis (Van Vuuren, 2007).
2.2. Toxicity studies
2.2.1. Brine-shrimp lethality assay
Artiﬁcial salt water was prepared by dissolving 32 g of Tropic
Marine® Sea Salt in 1 l of distilled water, of which 500 ml was added
to a bottomless, inverted plastic bottle. Dried, brine-shrimp (Artemia
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added to the salt water. To ensure a high hatch rate, a rotary pump
was used to aerate the water and disperse the eggs, and the eggs ex-
posed to a concentrated source of light from a lamp (220–240 V). The
eggs were incubated under these conditions for 18–24 h, at ambient
temperature. A volume of 400 μl salt water containing on average 40–
60 live brine-shrimp was added to each well of a 48 well micro-titre
plate. Thereafter, 400 μl sample (plant samples, antimicrobials or a
combination of both, all diluted in distilled water or 1% dimethyl
sulphoxide (DMSO) for organic extracts and essential oils) was added
to triplicatewells. All sampleswere tested for toxicity at a concentration
of 1 mg/ml, since a concentration above 1 mg/ml not resulting in brine-
shrimp death was considered non-toxic for the assay (Bussmann et al.,
2011). The negative control consisted of 32 g/l salt water and the
positive control consisted of 1.6 mg/ml potassium dichromate (Fluka).
The plates were observed under a light microscope (Olympus) (40×
magniﬁcation) immediately after sample addition (at time 0) for any
dead brine-shrimp, which would be excluded from percentage mortal-
ity calculations. Dead brine-shrimp were then counted after 24 and 48 h.
Thereafter, a lethal dose of 50 μl of glacial acetic acid (100% v/v;
Saarchem) was added to each well and a total dead brine-shrimp
count undertaken. The percentage mortality was then calculated
(Cock and Kalt, 2010). Samples providing a percentage mortality
greater than 50% were considered toxic (Bussmann et al., 2011).
These samples were then tested at concentrations of 1, 0.5, 0.25,
0.125, 0.063 and 0.031 mg/ml to obtain a log-sigmoid dose response
curve, generated with GraphPad Prism® software (Version 5), from
which the LC50 values were determined. The LC50 value represented
the concentration of a test substance necessary to have a lethal effect
on 50% of the brine-shrimp.
2.2.2. MTT cell proliferation assay
The human kidney epithelial (Graham or HEK-293) cells were cul-
tured in Dulbecco’s Modiﬁed Eagles Medium (Sigma-Aldrich) supple-
mented with 10% foetal bovine serum (FBS) (Thermo Scientiﬁc), 1%
non-essential amino acids (Sigma-Aldrich) and 1% penicillin/streptomy-
cin/fungizone mixture (10,000 U penicillin/ml, 10,000 μg streptomycin/
ml and 25 μg fungizone/ml) (Sigma-Aldrich). The cell line was main-
tained at 37 °C with 5% CO2, in accordance with the methods by
Mosmann (1983) and Van Zyl et al. (2006). A waiver for the use of the
human kidney epithelial (Graham) cell line was obtained from the
University of the Witwatersrand Human Research Ethics Committee
(Reference W-CJ-120309-3).
For experimental purposes, once conﬂuency of the cells had been
achieved, the trypsinised cells were re-suspended to a cell density of
0.5 million cells/ml. A volume of 180 μl of cell suspension was added
to each well of a sterile micro-titre plate before being incubated at
37 °C for 6 h in a humidiﬁed environment with 5% CO2. Samples were
screened at 100 μg/ml, in triplicate, per plate and all samples tested in
at least two independent experiments. A colour control for each sample
(absent of cell suspension) was included, along with two wells of a 0%
cell control (sample-free) and 14 wells of 100% cell suspension control
(sample-free). Quinine and camptothecin (100 μg/ml and 1 mg/ml;
Sigma-Aldrich) were included as the positive controls. The prepared
plates were incubated at 37 °C for 44 h. At which time, a washing
step was undertaken using PBS (pH 7.2), to ensure no interference by
the plant sample colour with the MTT absorbance readings and to min-
imize any interaction with the MTT. Thereafter, 40 μl MTT solution
(Sigma-Aldrich; 5 mg/ml) was added to each well and incubated for a
further 4 h. DMSO was then added to each well to stop the reaction
and to dissolve the formazan crystals.
The absorbance of the dissolved crystals was read using the
Labsystems iEMS MF reader, at a test wavelength of 540 nm and
reference wavelength of 690 nm. Percentage cellular viability was
then calculated using the following equation, where “Abs” signiﬁes ab-
sorbance, and all absorbance values used in the calculationwere derivedfrom deducting the absorbance value at 690 nm from the absorbance
value at 540 nm (Abs540− Abs690) (Kamatou, 2006):
%Cellviability ¼ Abstestsample– MeanAbscontrol–MeanAbsblankð Þ  100
MeanAbscontrol–MeanAbsblankð Þ :
2.3. Antimicrobial analysis
2.3.1. Minimum inhibitory concentration assays
Based on their prevalence to cause nosocomial infections, the fol-
lowing micro-organisms were studied; three Gram-positive bacteria,
Staphylococcus aureus (American Type Culture Collection (ATCC)
25923), Enterococcus faecalis (ATCC 29212) and Bacillus cereus (ATCC
11778), three Gram-negative bacteria; Klebsiella pneumoniae (ATCC
13883), Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa
(ATCC 27858), along with two yeasts; Candida albicans (ATCC 10231)
and Cryptococcus neoformans (ATCC 14116). All micro-organisms were
cultured in Tryptone Soya broth (TSB) (Oxoid) and kept viable by sub-
culturing. Streak plates were prepared to ensure the purity of the cul-
ture, as well as for isolation of pure colonies for sub-culturing. The bac-
teria were incubated at 37 °C for 24 h and the yeasts at 25 °C for 48 h. A
waiver for the use of these micro-organisms was obtained from the
University of the Witwatersrand Human Research Ethics Committee
(Reference W-CJ-130726-1).
The conventional antimicrobials included erythromycin (potency
of≥850 μg/mg), gentamicin (potency of 600 μg/mg), nystatin (potency
of ≥4400 United States Pharmacopeia (USP) units/mg), penicillin G
(potency of 1440–1680 units/mg), tetracycline [≥95% High Perfor-
mance Liquid Chromatography (HPLC)], ciproﬂoxacin (≥98% HPLC)
and amphotericin B (80% HPLC), which were all purchased from
Sigma-Aldrich (South Africa). The antibiotics were prepared in sterile
distilled water, to a concentration of 0.01 mg/ml and the antifungals
were prepared to 0.1 mg/ml. Amphotericin B was initially solubilized
in 1% (v/v) DMSO before further additions of sterile water.
The MIC assay was used to evaluate the antimicrobial activity of the
plant samples and the conventional antimicrobials independently,
followed by evaluation in combination. The guidelines for the micro-
titre plate method, to determine the antibacterial activity of plant sam-
ples were in accordance with methods by Eloff (1998). The Clinical and
Laboratory Standards Institute (CLSI) guidelines (2012) were followed
when analysing the conventional antimicrobials.
Each well of the micro-titre plate was ﬁlled with 100 μl of sterilized
distilled water. The individual plant samples and conventional antimi-
crobials were then introduced into the wells of the ﬁrst row, as 100 μl
for individual samples or 50 μl of each agent in the double combination.
Plant samples were introduced at a starting concentration of 32 mg/ml
in acetone (organic extracts) or sterile water (aqueous extracts). The
conventional antimicrobialswere introduced at a starting concentration
of 0.01 mg/ml for antibiotics and 0.1 mg/ml for antifungal agents. The
positive control, to ensure antimicrobial susceptibility of pathogens,
consisted of 0.1 mg/ml amphotericin B or 0.01 mg/ml ciproﬂoxacin for
yeasts and bacteria, respectively. A solvent control comprising of the ac-
etone solvent whereby sterile water (used to replace sample) was
diluted to 32 mg/ml was tested to ensure that the solvent used did
not itself exhibit antimicrobial activity. A negative control was included
(comprising of media and test organism), to ensure that the media was
capable of supporting microbial growth. After the addition of the sam-
ples to the plate, the serial doubling dilution method was employed.
The prepared micro-titre plates were then inoculated with the relevant
pathogen, with each inoculum having a size of approximately 1 × 106
colony forming units (CFU)/ml. Plates, sealed with a sterile adhesive
sealer, were then incubated at 25 °C for 48 h and 37 °C for 24 h for yeasts
and bacteria, respectively.
After incubation, 40 μl of the colour indicator, 0.40 mg/ml ρ-
iodonitrotetrazolium violet (INT; Sigma-Aldrich), was added to each
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The end point MIC value was then taken as the lowest concentration
of test sample that resulted in the inhibition of growth, which was
seen by the absence of the purple-pink colour of the indicator. All sam-
ples and their combinations were tested in at least duplicate. Extracts
and essential oils were considered to exhibit noteworthy antimicrobial
activity for MIC values b1 mg/ml and ≤2 mg/ml, respectively (Duarte
et al., 2005; Rios and Recio, 2005; Van Vuuren, 2008).
2.3.2. Fractional inhibitory concentration (FIC) assessment
Interactions between the combinations of plant samples and con-
ventional antimicrobials were further classiﬁed using the sum of the
fractional inhibitory concentration (∑FIC). The FIC was calculated
using the following equation, where (a) represents the plant sample
and (b) the conventional antimicrobial sample (Van Vuuren and
Viljoen, 2011);
FIC ið Þ ¼MIC að Þ incombinationwith bð Þ
MIC að Þindependently
FIC iið Þ ¼MIC bð Þincombinationwith að Þ
MIC bð Þindependently :
The ∑FIC was then calculated using the equation: ∑FIC =
FIC(i) + FIC(ii). The interactions were classiﬁed as being synergistic
for∑FIC values of ≤0.5, additive (N0.5–1.0), indifferent (N1.0–≤4.0)
or antagonistic (N4.0) (Van Vuuren and Viljoen, 2011). Tentative inter-
pretations were included where the MIC value were greater than the
highest concentration tested to provide an estimation of what the pos-
sible interactive proﬁle for the combination could have been. These in-
terpretations were not given a ∑FIC value, as only absolute values
could be used in∑FIC calculations.
2.3.3. Varied ratio combination studies (isobolograms)
For notable synergistic or antagonistic interactions, nine different
ratios of the combination were prepared and the MIC values deter-
mined. The samples were combined at ﬁxed concentrations of 0.01 or
0.1 mg/ml for antibiotics or antifungals, respectively, and 32 mg/ml
for the plant sample, at various volume ratios (antimicrobial:plant),
resulting in varied concentrations for each ratio (Table 2). Data points
for each ratio studied were plotted on an isobologram using the
GraphPad Prism® software (Version 5). The construction of isobolograms
allowed for the identiﬁcation of the agent (plant or antimicrobial sample)
most responsible for the synergistic or antagonistic effects within the
combination. Data points falling belowand including the 0.5:0.5 line indi-
cated synergy, while those above the 0.5:0.5 line, up to and including the
1.0:1.0 line indicated an additive interaction. Data points above the
1.0:1.0 line, up to and including the 4.0:4.0 line indicated a non-Table 2
The concentration ratios used for antimicrobial and plant sample combination studies.
Volume ratio of antimicrobial:
plant sample (μl)
Concentration of antibacteriala
in combination (μg/ml)
90:10 9.00
80:20 8.00
70:30 7.00
60:40 6.00
50:50 5.00
40:60 4.00
30:70 3.00
20:80 2.00
10:90 1.00
a Ciproﬂoxacin/erythromycin/gentamicin/penicillin G/tetracycline.
b Amphotericin B/nystatin.
c Samples include all the essential oils, organic and aqueous extracts of the plants indicating n
in the form of isobolograms).interactive or indifferent interaction and data points falling above the
4.0:4.0 line indicated antagonism (Van Vuuren and Viljoen, 2011).
3. Results and discussion
The percentage yield for each extract, as well as each essential oil
was calculated and has been recorded in Table 3.
3.1. Toxicity studies
Two assays, namely the BSLA and theMTT assay were used to assess
the toxicity of the individual samples and eight notable combinations
(essential oil, aqueous and organic extracts of A. betulina and A. afra in
combination with ciproﬂoxacin, and the aqueous and organic extracts
of S. frutescenswith ciproﬂoxacin), identiﬁed in the antimicrobial stud-
ies. The BSLA was undertaken for the preliminary toxicity screening;
however, the MTT assay provided a cellular evaluation of toxicity.
3.1.1. Brine-shrimp lethality assay
All plant samples (extracts and oils) and antimicrobials were indi-
vidually screened at 1 mg/ml. The extracts were only considered toxic
if they induced percentage mortalities greater than 50% (LC50)
(Bussmann et al., 2011). Three individual plant samples were found to
show toxicity, namely A. betulina essential oil, and the organic extracts
of L. javanica and S. frutescens, demonstrating a percentage mortality
of 100% (LC50: 0.31 ± 0.03 mg/ml), 70.13 ± 5.29% (LC50: 0.51 ±
0.03 mg/ml) and 82.69± 4.51% (LC50: 0.45± 0.05 mg/ml), respective-
ly. When tested individually, the antimicrobials demonstrated no toxic-
ity in the BSLA (Table 4).
3.1.2. MTT cell proliferation assay
The plant samples and conventional antimicrobials, all individually
screened at 100 μg/ml, demonstrated no toxicity toward the human
kidney epithelial cells, however, two of the essential oils (A. betulina
and A. afra) demonstrated a potential for toxicitywith a cellular viability
of 64.10 ± 6.29% and 68.28 ± 4.64%, respectively (Table 4).
3.2. Antimicrobial studies
TheMIC results for the antimicrobial studies undertaken on the indi-
vidual samples have been recorded in Tables 5.1 and 5.2, respectively.
All conventional antimicrobials fell within the break point expectation
ranges (Andrews, 2004; CLSI, 2012), except for tetracycline against
E. faecalis and P. aeruginosa, where a reduced susceptibility was noted,
possibly due to emerging resistance by the strain tested. The individual
plant samples demonstrated mostly weak antimicrobial activity, which
is in accordance with the literature (Table 1). L. javanica demonstrated
the best activity, where noteworthy susceptibility was observed against
six of the eight tested pathogens. The organic extract of L. javanica alsoConcentration of antifungalb
in combination (μg/ml)
Concentration of plant samplec
in combination (mg/ml)
90.00 3.20
80.00 6.40
70.00 9.60
60.00 12.80
50.00 16.00
40.00 19.20
30.00 22.40
20.00 25.60
10.00 28.80
otable interactionswith conventional antimicrobials (results of which have been provided
Table 3
Percentage yield values for all the plant samples investigated.
Plant Plant part used in analysis Percentage yield (% w/w)
Essential oil Aqueous extract Organic extract
Agathosma betulina Leaves 1.54 1.43 4.80
Aloe ferox Leaves NA 4.14 2.99
Artemisia afra Leaves and twigs 0.32 9.91 8.16
Lippia javanica Leaves 0.69 8.31 11.16
Pelargonium sidoides Roots (tubers) NA 7.84 3.18
Sutherlandia frutescens Leaves NA 11.42 5.89
NA = plant not aromatic in nature and hence no essential oil could be distilled, or in the case of the aromatic plant, P. sidoides, an insufﬁcient quantity of essential oil could be obtained
from the roots.
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pared to the other tested plant samples (Table 5.2).
A total of 420 conventional antimicrobial:medicinal plant combina-
tions were tested for interactive antimicrobial activity (Tables 6.1, 6.2
and 6.3). Of the 420 combinations, 14.29% were synergistic, 7.56% an-
tagonistic, 35.71% additive and 42.44% were indifferent or non-
interactive in nature. A few notable synergistic and antagonistic interac-
tions were identiﬁed in this current study, such as the combinations of
ciproﬂoxacin with A. betulina (essential oil, aqueous and organic
extracts), A. afra (essential oil and organic extract) and S. frutescens
(organic extract) showing synergistic interactions against E. coli. In con-
trast, A. afra aqueous extract demonstrated a signiﬁcant antagonistic in-
teraction with ciproﬂoxacin against E. coli.
3.3. Notable combinations
3.3.1. Ciproﬂoxacin in combination with A. betulina
The combination of A. betulinawith ciproﬂoxacin provided a notable
interactive proﬁle, when tested against E. coli, which is most commonly
the cause of UTI's. In orthodox medicine, ﬂuoroquinolones, such asTable 4
Mortality (%) and cell death (%) results for samples tested individually in the BSLA and MTT as
Sample Mortality
After 24
Antimicrobials Ciproﬂoxacin 0.00
Erythromycin 0.00
Gentamicin 1.12 ± 0
Penicillin G 0.00
Tetracycline 0.00
Amphotericin B 0.00
Nystatin 0.00
Essential oils A. betulina 100.00 ±
A. afra 0.00
L. javanica 0.58 ± 0
Aqueous extracts A. betulina 0.00
A. ferox 0.00
A. afra 0.00
L. javanica 0.00
P. sidoides 0.00
S. frutescens 0.00
Organic extracts A. betulina 0.00
A. ferox 0.00
A. afra 0.00
L. javanica 0.00
P. sidoides 0.00
S. frutescens 13.46 ±
Controls Quinine 0.00a,b
Camptothecin 0.00a
30.00 ±
Potassium dichromate 100.00 ±
S.D. = standard deviation; NT = control not tested in the assay. Cell death (%) = 100 – cell v
a Tested at a concentration of 1 mg/ml.
b Tested at a concentration of 100 μg/ml.
c Tested at a concentration of 1.6 mg/ml.ciproﬂoxacin, have been used in the treatment of UTI's for many
years (Merck Manual, 2006; SAMF, 2012). In traditional medicine,
A. betulina is very often ingested orally, as an aqueous infusion or alco-
holic tincture, for the treatment of UTI's (Watt and Breyer-Brandwijk,
1962; Hutchings et al., 1996; VanWyk et al., 2009). The aqueous extract
of A. betulina showed a promising synergistic effect in combinationwith
ciproﬂoxacin, when tested against E. coli. TheMIC values of the aqueous
extract (90 μg/ml) and ciproﬂoxacin (0.03 μg/ml) in combination
(Table 6.2) were well below the MIC values for the agents when tested
individually (≥8.00 mg/ml for the aqueous extract and 0.08 μg/ml for
ciproﬂoxacin) (Tables 5.2 and 5.1, respectively), thereby demonstrating
a tentative∑FIC interpretation of synergy.
When the organic extract of A. betulina was combined with cipro-
ﬂoxacin and tested against E. coli, a tentative∑FIC interpretation of
synergy was also identiﬁed. As observed with the aqueous extract: cip-
roﬂoxacin combination, the MIC values for the agents in combination
(Table 6.2) were well below the MIC values of the agents when tested
individually (Tables 5.1 and 5.2), thereby demonstrating a synergistic
interaction. The essential oil of A. betulina in combination with
ciproﬂoxacin, when tested against E. coli, demonstrated a tentativesay, respectively (n = 6).
± S.D. (%)a Cell death ± S.D. (%)b
h: After 48 h: After 48 h:
0.00 0.10 ± 0.01
0.00 0.10 ± 0.01
.58 8.99 ± 0.33 0.10 ± 0.01
0.00 0.10 ± 0.01
6.67 ± 1.16 0.10 ± 0.01
0.00 5.93 ± 3.41
0.00 0.10 ± 0.01
0.00 100.00 ± 0.00 35.90 ± 6.29
1.39 ± 0.58 31.72 ± 4.64
.52 1.17 ± 0.71 0.10 ± 0.01
0.00 0.10 ± 0.01
0.00 0.10 ± 0.01
0.00 0.10 ± 0.01
1.43 ± 0.58 0.10 ± 0.01
3.45 ± 0.58 0.10 ± 0.01
0.00 0.10 ± 0.01
0.00 0.10 ± 0.01
0.00 0.10 ± 0.01
0.00 0.10 ± 0.01
70.13 ± 5.29 0.10 ± 0.01
0.00 0.10 ± 0.01
0.58 82.69 ± 4.51 0.10 ± 0.01
0.00a
11.76 ± 1.00b
71.38 ± 4.73a
0.10 ± 0.01b
2.00b
2.08 ± 0.58a
100.00 ± 0.00b
76.07 ± 2.94a
0.10 ± 0.01b
0.00c NT
iability (%).
Table 5.1
Minimum inhibitory concentration (MIC) values (μg/ml) for all conventional
antimicrobials, when tested individually.
Test organism Antibiotics Antifungals
Cip Ery Gen Pen Tet Amp Nys
S. aureus (ATCC 25923) 0.47 0.31 1.88 ≥2.50 0.23 NT NT
B. cereus (ATCC 11778) 0.63 0.31 ≥2.50 ≥2.50 0.16 NT NT
E. faecalis (ATCC 29212) 1.25 1.25 ≥2.50 ≥2.50 ≥2.50 NT NT
E. coli (ATCC 25922) 0.08 NA ≥2.50 NT 1.25 NT NT
K. pneumoniae (ATCC 13883) 0.63 NA ≥2.50 NT 1.25 NT NT
P. aeruginosa (ATCC 27853) 0.16 NA 0.31 NT ≥2.50 NT NT
C. albicans (ATCC 10231) NT NT NT NT NT 1.56 2.34
C. neoformans (ATCC 14116) NT NT NT NT NT 0.39 1.56
Cip = ciproﬂoxacin; Ery = erythromycin; Gen = gentamicin; Pen = penicillin G;
Tet = tetracycline; Amp = amphotericin B; Nys = nystatin; NT = micro-organism is
not susceptible to the antimicrobial; ≥2.50 = antimicrobial samples were not tested at
higher concentrations for the determination of a MIC value.
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191Z. Hübsch et al. / South African Journal of Botany 93 (2014) 185–197synergistic interaction (Table 6.2); however, this interaction would not
be relevant for the treatment of urinary tract infections, since the essen-
tial oil is not used traditionally in this manner of oral ingestion.
Since the combination between A. betulina (essential oil, aqueous
and organic extracts) and ciproﬂoxacin against E. coli provided such a
notable synergistic proﬁle, the combinations were tested at varying ra-
tios.Most ratioswere found in the synergistic or additive region of Fig. 1,
with only four ciproﬂoxacin: A. betulina ratios (9:1; 8:2; 7:3 and 3:7) of
the organic extract and one ratio (7:3) (refer to Table 2, for ratio concen-
trations) of the essential oil, indicating an indifferent interaction. The
identiﬁed synergistic interactions could possibly lead to more effective
treatment of UTI's and reverse the resistance of E. coli toward ciproﬂox-
acin, however, further in vivo testing would be warranted to support
such claims.
When the combinations of ciproﬂoxacin with A. betulina (essential
oil, aqueous and organic extracts) were tested for toxicity, none of the
combinations were found to show toxicity, with a 0.00% mortality and
cell viability no less than 100% in the BSLA andMTT assays, respectively.
3.3.2. Ciproﬂoxacin in combination with A. afra
The organism, E. coli, is commonly responsible for infectious gastro-
intestinal complaints, which could arise from eating contaminated food
or drinking contaminated water. In rural areas, these complaints are
often treated with the medicinal plant, A. afra, in comparison to ﬂuoro-
quinolone or ciproﬂoxacin usage, in orthodoxmedicine (MerckManual,
2006; SAMF, 2012). The essential oil and organic extract of A. afra in
combination with ciproﬂoxacin displayed synergistic interactions
against E. coli (∑FIC of 0.27 for both combinations) (Table 6.2). In con-
trast, the aqueous extract combination demonstrated an antagonistic
interaction with ciproﬂoxacin against E. coli (∑FIC of 8.55)
(Table 6.2). A. afra is most commonly consumed orally as an aqueous
infusion (herbal tea) for the treatment of gastrointestinal complaints
and hence the antagonistic interaction noted here may warrant caution
and require further pharmacokinetic studies to further investigate the
mechanism of the interaction.
The combination of essential oil, aqueous or organic extractwith cip-
roﬂoxacin, was tested in varied ratios against E. coli, since these combi-
nations showed variance in interactive proﬁles, ranging from
synergistic to highly antagonistic interactions. In the varied ratio studies
(Fig. 2), the∑FIC evaluation of antagonism for the aqueous extract
combination (Table 5.2) was supported by the ratio containing the
equal volumes (5:5). Similarly, the∑FIC evaluation of synergy for the
organic extract combination, as well as the essential oil combination
was supported in the varied ratio study (Fig. 2). Even though the ratio
containing equal volumes of each agent for this combination was
found to be synergistic, some ratios were found in the antagonistic re-
gion for both the organic extract and essential oil combinations when
combined with ciproﬂoxacin (Fig. 2). Therefore, combinations of
Table 6.1
MIC (μg/ml) and∑FIC values for the plant: antibiotic combinations, against the Gram-positive bacterial strains.
Combination S. aureus
(ATCC 25923)
B. cereus
(ATCC 11778)
E. faecalis
(ATCC 29212)
Aq
AM
∑FIC (Int.) Org
AM
∑FIC (Int.) EO
AM
∑FIC (Int.) Aq
AM
∑FIC (Int.) Org
AM
∑FIC (Int.) EO
AM
∑FIC (Int.) Aq
AM
∑FIC (Int.) Org
AM
∑FIC (Int.) EO
AM
∑FIC (Int.)
A. betulina + ciproﬂoxacin 2000
0.63
1.59
(IND)
2000
0.63
2.34
(IND)
1000
0.32
1.18
(IND)
1000
0.32
T
(ADD)
500
0.16
0.92
(ADD)
1000
0.32
2.10
(IND)
3000
0.94
T
(IND)
2000
0.63
1.50
(IND)
1500
0.47
T
(ADD)
A. betulina + erythromycin 1000
0.32
1.16
(IND)
2000
0.63
3.03
(IND)
1000
0.32
1.53
(IND)
1000
0.32
T
(IND)
500
0.16
1.19
(IND)
380
0.12
0.99
(ADD)
3000
0.94
T
(IND)
≥4000
≥1.25
T
(IND)
2000
0.63
T
(ADD)
A. betulina + gentamicin ≥4000
≥1.25
1.17
(IND)
1500
0.47
1.00
(ADD)
1000
0.32
0.67
(ADD)
2000
0.63
T
(SYN)
2000
0.63
T
(SYN)
≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(ADD)
1000
0.32
T
(ADD)
≥4000
≥1.25
T
(ADD)
A. betulina + penicillin G ≥4000
≥1.25
T
(ADD)
2000
0.63
1.25
(IND)
1000
0.32
0.63
(ADD)
≥4000
≥1.25
T
(ADD)
1000
0.32
1.46
(IND)
750
0.23
1.29
(IND)
≥4000
≥1.25
T
(ADD)
1500
0.47
0.94
(ADD)
≥4000
≥1.25
T
(ADD)
A. betulina + tetracycline 500
0.16
0.76
(ADD)
500
0.16
0.95
(ADD)
500
0.16
0.95
(ADD)
190
0.12
T
(ADD)
190
0.06
0.63
(ADD)
130
0.04
0.46
(SYN)
≥4000
≥1.25
T
(ADD)
1000
0.32
T
(ADD)
≥4000
≥1.25
T
(ADD)
A. ferox + ciproﬂoxacin ≥4000
≥1.25
T
(IND)
1000
0.32
0.93
(ADD)
NA ≥4000
≥1.25
T
(IND)
2000
0.63
1.67
(IND)
NA 2000
0.63
T
(ADD)
2000
0.63
T
(ADD)
NA
A. ferox + erythromycin 1000
0.32
T
(IND)
1000
0.32
1.28
(IND)
NA 500
0.16
T
(ADD)
500
0.08
0.34
(SYN)
NA 2000
0.63
T
(ADD)
2000
0.63
T
(ADD)
NA
A. ferox + gentamicin ≥4000
≥1.25
T
(ADD)
1500
0.47
1.00
(ADD)
NA 3000
0.94
T
(ADD)
≥4000
≥1.25
T
(ADD)
NA ≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(ADD)
NA
A. ferox + penicillin G 2000
0.63
T
(ADD)
2000
0.63
0.75
(ADD)
NA 2000
0.63
T
(ADD)
750
0.24
0.35
(SYN)
NA ≥4000
≥1.25
T
(ADD)
1500
0.47
0.94
(ADD)
NA
A. ferox + tetracycline ≥4000
≥1.25
T
(ANT)
750
0.24
1.23
(IND)
NA ≥4000
≥1.25
T
(ANT)
190
0.06
0.63 NA ≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(ADD)
NA
A. afra + ciproﬂoxacin ≥4000
≥1.25
T
(ANT)
500
0.16
1.34
(IND)
2000
0.63
2.34
(IND)
≥4000
≥1.25
T
(IND)
500
0.16
1.57
(IND)
1000
0.32
1.01
(IND)
≥4000
≥1.25
T
(IND)
2000
0.63
1.50
(IND)
2000
0.63
T
(ADD)
A. afra + erythromycin 1000
0.32
1.53
(IND)
500
0.16
1.52
(IND)
1000
0.32
1.53
(IND)
750
0.23
T
(ADD)
250
0.08
0.92
(ADD)
500
0.16
0.77
(ADD)
≥4000
≥1.25
T
(IND)
2000
0.63
1.50
(IND)
2000
0.63
T
(ADD)
A. afra + gentamicin ≥4000
≥1.25
T
(IND)
1000
0.32
2.17
(IND)
1000
0.32
0.67
(ADD)
≥4000
≥1.25
T
(IND)
1000
0.32
T
(SYN)
≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(ADD)
1000
0.32
T
(ADD)
≥4000
≥1.25
T
(ADD)
A. afra + penicillin G 1500
0.47
0.94
(ADD)
2000
0.63
4.25
(ANT)
2000
0.63
1.25
(IND)
750
0.24
T
(SYN)
1500
0.47
4.40
(ANT)
1000
0.32
0.63
(ADD)
1000
0.32
T
(SYN)
2000
0.63
1.25
(IND)
2000
0.63
T
(ADD)
A. afra + tetracycline 1000
0.32
1.89
(IND)
500
0.16
1.70
(IND)
500
0.16
0.95
(ADD)
190
0.06
T
(SYN)
130
0.04
0.59
(ADD)
190
0.06
0.48
(SYN)
≥4000
≥1.25
T
(ADD)
1000
0.32
T
(ADD)
≥4000
≥1.25
T
(ADD)
L. javanica + ciproﬂoxacin 2000
0.63
1.84
(IND)
100
0.05
0.51
(ADD)
500
0.16
0.67
(ADD)
2000
0.63
T
(IND)
130
0.04
T
(SYN)
500
0.16
0.58
(ADD)
≥4000
≥1.25
T
(IND)
1000
0.32
1.26
(IND)
750
0.24
0.44
(SYN)
L. javanica + erythromycin 1000
0.32
1.28
(IND)
500
0.16
2.52
(IND)
1000
0.32
1.70
(IND)
500
0.16
T
(ADD)
20
0.005
T
(SYN)
190
0.06
0.32
(SYN)
2000
0.63
T
(ADD)
250
0.08
0.32
(SYN)
3000
0.94
1.75
(IND)
L. javanica + gentamicin ≥4000
≥1.25
T
(IND)
130
0.04
0.54
(ADD)
750
0.24
0.63
(ADD)
≥4000
≥1.25
T
(ADD)
130
0.04
T
(SYN)
≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(ADD)
130
0.04
T
(SYN)
2000
0.63
T
(ADD)
L. javanica + penicillin G ≥4000
≥1.25
T
(IND)
750
0.23
3.09
(IND)
1000
0.32
0.80
(ADD)
2000
0.63
T
(ADD)
750
0.24
T
(SYN)
1000
0.32
0.80
(ADD)
2000
0.63
T
(ADD)
2000
0.63
2.25
(IND)
2000
0.63
0.92
(ADD)
L. javanica + tetracycline 1000
0.32
1.64
(IND)
380
0.12
2.04
(IND)
500
0.16
1.03
(IND)
250
0.08
T
(ADD)
20
0.005
T
(SYN)
130
0.04
0.34
(SYN)
≥4000
≥1.25
T
(ADD)
500
0.16
T
(ADD)
≥4000
≥1.25
T
(IND)
P. sidoides + ciproﬂoxacin 750
0.24
0.89
(ADD)
750
0.24
1.01
(IND)
NA 500
0.16
0.50
(SYN)
380
0.12
0.44
(SYN)
NA 1500
0.47
1.88
(IND)
1000
0.32
0.76
(ADD)
NA
P. sidoides + erythromycin 500
0.16
0.77
(ADD)
500
0.16
0.85
(ADD)
NA 259
0.08
0.39
(SYN)
190
0.06
0.32
(SYN)
NA 1500
0.47
1.88
(IND)
1500
0.47
1.13
(IND)
NA
P. sidoides + gentamicin 500
0.16
0.34
(SYN)
500
0.16
0.42
(SYN)
NA 1000
0.32
T
(SYN)
1000
0.32
T
(SYN)
NA 2000
0.63
T
(IND)
1500
0.47
T
(ADD)
NA
P. sidoides + penicillin G 500
0.16
0.32
(SYN)
250
0.08
0.20
(SYN)
NA 2000
0.63
1.25
(IND)
750
0.24
0.60
(ADD)
NA 1000
0.32
1.13
(IND)
380
0.12
0.24
(SYN)
NA
P. sidoides + tetracycline 250
0.08
0.48
(SYN)
500
0.16
1.03
(IND)
NA 250
0.08
0.63
(ADD)
190
0.06
0.51
(ADD)
NA 1000
0.32
T
(IND)
1000
0.32
T
(ADD)
NA
S. frutescens + ciproﬂoxacin ≥4000
≥1.25
T
(IND)
1000
0.32
1.18
(IND)
NA 1000
0.32
T
(ADD)
750
0.24
1.38
(IND)
NA 2000
0.63
T
(ADD)
1000
0.32
0.51
(ADD)
NA
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193Z. Hübsch et al. / South African Journal of Botany 93 (2014) 185–197ciproﬂoxacin and A. afra are highly dose-dependent. Interestingly, the
ratio of 3:7 (ciproﬂoxacin: A. afra) was found in the antagonistic region,
for all three plant sample types (essential oil, aqueous and organic ex-
tracts) prepared from A. afra (Fig. 2), thus indicating that a higher con-
centration of A. aframay be responsible for the antagonism noted.
When testing the toxicity of the combination of ciproﬂoxacin with
A. afra (essential oil, aqueous and organic extracts), none of the combi-
nations were found to show toxicity in either the BSLA or MTT assay,
compared to the positive controls at either 24 or 48 h of exposure. In
the BSLA, the essential oil and aqueous extract combination with
ciproﬂoxacin showed a 1.25± 1.00% and 0.00%mortality after 48 h, re-
spectively. The organic extract combination with ciproﬂoxacin demon-
strated a 2.13 ± 0.58% mortality within the ﬁrst 24 h of exposure, with
no further death occurring thereafter. These mortality rates were not
considered signiﬁcant enough for a varied ratio toxicity study to be un-
dertaken, since mortality rates were well below 50%.
3.3.3. Ciproﬂoxacin in combination with S. frutescens
The combination of ciproﬂoxacin with S. frutescens demonstrated
a notable synergistic proﬁle against E. coli (Table 6.2). As with
A. betulina, S. frutescens is amedicinal plant commonly used in the treat-
ment of UTI's. Therefore it was of interest to observe the potential of this
combination (Merck Manual, 2006; SAMF, 2012). Since S. frutescens is
commonly ingested orally as an alcoholic tincture for the treatment of
UTI's, results obtained from the organic extract in combination would
most closely depict the possible interactions between ciproﬂoxacin
and S. frutescens, when consumed in the traditional form. The organic
extract of S. frutescens when combined with ciproﬂoxacin showed
a favourable synergistic interaction against E. coli (∑FIC of 0.28)
(Table 6.2). S. frutescens can also be consumed as a herbal tea, therefore
the combination with the aqueous extract was also evaluated in varied
ratios (Table 5.2).
When examining the various mixtures, most ratios for both the
aqueous and organic extract combinations with ciproﬂoxacin were
found in the additive region (Fig. 3). Three ciproﬂoxacin: S. frutescens ra-
tios (6:4; 5:5 and 3:7) (refer to Table 2, for ratio concentrations) for the
organic extract combination were found below or on the 0.5:0.5 line,
thereby demonstrating a synergistic interaction. Only one ciproﬂoxacin:
S. frutescens ratio point (1:9) for the organic extract was found in the in-
different region. Four of the ratios (7:3; 3:7; 2:8; 1:9) for the aqueous
extract combination were found in the indifferent region (Fig. 3).
When the combinations of ciproﬂoxacin and S. frutescens (aqueous
and organic extracts) were tested for toxicity in the BSLA, none of the
combinations were found to show toxicity. The aqueous extract combi-
nation showed a 0.00% mortality, however, the organic extract combi-
nation demonstrated a 2.55 ± 0.58% and 39.49 ± 2.08% mortality,
after 24 and 48 h, respectively. However, the mortalities were still
below 50% and therefore not considered toxic in nature for the BSLA.
Similarly, in the MTT assay the combinations demonstrated no toxicity
compared to the positive controls.
3.4. General discussion of medicinal plant:conventional antimicrobial
combinations
A review by Van Vuuren and Viljoen (2011), documented numerous
combinations of plants with conventional antimicrobials. A summary of
the results formany combination studieswere given,wheremost often,
synergy had been reported. In the review, no studies were foundwhere
conventional antimicrobials were investigated in combination with the
Southern African medicinal plants selected for analysis in this study.
This further demonstrates the lack of information pertaining to interac-
tive Southern African medicinal plant:antimicrobial combinations and
thus highlights the need for the scientiﬁc investigation of these combi-
nations. A previous study was found where S. frutescens in combination
with antiretroviral medication reduced the efﬁcacy of the antiretroviral
drugs (Mills et al., 2005). Fasinu et al. (2013b) also found the potential
Table 6.2
MIC (μg/ml) and∑FIC values for the plant: antibiotic combinations, against the Gram-negative bacterial strains.
Combination E. coli
(ATCC 25922)
K. pneumoniae
(ATCC 13883)
P. aeruginosa
(ATCC 27853)
Aq
AM
∑FIC (Int.) Org
AM
∑FIC (Int.) EO
AM
∑FIC (Int.) Aq
AM
∑FIC (Int.) Org
AM
∑FIC (Int.) EO
AM
∑FIC (Int.) Aq
AM
∑FIC (Int.) Org
AM
∑FIC (Int.) EO
AM
∑FIC (Int.)
A. betulina + ciproﬂoxacin 90
0.03
T
(SYN)
50
0.02
T
(SYN)
70
0.02
T
(SYN)
1500
0.47
T
(ADD)
750
0.23
T
(SYN)
190
0.06
T
(SYN)
500
0.16
T
(IND)
250
0.08
0.56
(ADD)
500
0.16
1.13
(IND)
A. betulina + gentamicin ≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(ADD)
1000
0.32
T
(SYN)
2000
0.63
T
(SYN)
≥4000
≥1.25
T
(ADD)
750
0.23
T
(ADD)
500
0.16
0.65
(ADD)
500
0.16
0.65
(ADD)
A. betulina + tetracycline ≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
3000
0.94
T
(IND)
≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
A. ferox + ciproﬂoxacin 2000
0.63
T
(ANT)
50
0.02
T
(SYN)
NA ≥4000
≥1.25
T
(IND)
3000
0.94
T
(IND)
NA 1500
0.47
3.19
(IND)
750
0.23
1.57
(IND)
NA
A. ferox + gentamicin ≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(ADD)
NA 3000
0.94
T
(ADD)
≥4000
≥1.25
T
(ADD)
NA ≥4000
≥1.25
T
(ANT)
≥4000
≥1.25
T
(ANT)
NA
A. ferox + tetracycline ≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
NA ≥4000
≥1.25
T
(IND)
2000
0.63
T
(ADD)
NA 2000
0.63
T
(ADD)
≥4000
≥1.25
T
(IND)
NA
A. afra + ciproﬂoxacin 2000
0.63
8.55
(ANT)
70
0.02
0.27
(SYN)
70
0.02
0.27
(SYN)
3000
0.94
2.24
(IND)
750
0.23
0.75
(ADD)
1000
0.32
T
(ADD)
1500
0.47
3.69
(IND)
250
0.08
0.67
(ADD)
500
0.16
1.13
(IND)
A. afra + gentamicin ≥4000
≥1.25
T
(IND)
2000
0.63
0.92
(ADD)
≥4000
≥1.25
T
(IND)
2000
0.63
T
(ADD)
1000
0.32
T
(ADD)
≥4000
≥1.25
T
(ADD)
1500
0.47
2.27
(IND)
500
0.16
0.85
(ADD)
500
0.16
0.65
(ADD)
A. afra + tetracycline ≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
3000
0.94
2.25
(IND)
≥4000
≥1.25
T
(IND)
2000
0.63
T
(IND)
1000
0.32
T
(SYN)
≥4000
≥1.25
T
(IND)
L. javanica + ciproﬂoxacin 500
0.16
2.25
(IND)
70
0.02
0.32
(SYN)
30
0.01
0.14
(SYN)
3000
0.94
T
(ADD)
130
0.04
0.19
(SYN)
1500
0.47
1.25
(IND)
1000
0.32
2.50
(IND)
250
0.08
0.56
(ADD)
750
0.23
1.82
(IND)
L. javanica + gentamicin ≥4000
≥1.25
T
(IND)
3000
0.94
2.38
(IND)
≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(ADD)
250
0.08
T
(SYN)
2000
0.63
T
(ADD)
≥4000
≥1.25
T
(ANT)
250
0.08
0.32
(SYN)
500
0.16
0.77
(ADD)
L. javanica + tetracycline ≥4000
≥1.25
T
(IND)
2000
0.63
2.50
(IND)
2000
0.63
1.50
(IND)
3000
0.94
T
(IND)
1500
0.47
1.88
(IND)
≥4000
≥1.25
T
(IND)
3000
0.94
T
(IND)
500
0.16
T
(SYN)
1500
0.47
T
(ADD)
P. sidoides + ciproﬂoxacin 1000
0.32
T
(ANT)
50
0.02
T
(SYN)
NA 3000
0.94
T
(ADD)
2000
0.63
T
(IND)
NA ≥4000
≥1.25
T
(ANT)
≥4000
≥1.25
T
(ANT)
NA
P. sidoides + gentamicin ≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(ADD)
NA 1000
0.32
T
(SYN)
500
0.16
T
(SYN)
NA ≥4000
≥1.25
T
(ANT)
≥4000
≥1.25
T
(ANT)
NA
P. sidoides + tetracycline ≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
NA ≥4000
≥1.25
T
(IND)
≥4000
≥1.25
T
(IND)
NA 1000
0.32
T
(ADD)
1500
0.47
T
(IND)
NA
S. frutescens + ciproﬂoxacin 500
0.16
T
(IND)
50
0.02
0.28
(SYN)
NA ≥4000
≥1.25
T
(IND)
2000
0.63
T
(IND)
NA 2000
0.63
T
(ANT)
250
0.08
0.56
(ADD)
NA
S. frutescens + gentamicin ≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(IND)
NA ≥4000
≥1.25
T
(ADD)
≥4000
≥1.25
T
(ADD)
NA ≥4000
≥1.25
T
(ANT)
380
0.23
0.84
(ADD)
NA
S. frutescens + tetracycline ≥4000
≥1.25
T
(IND)
3000
0.94
2.25
(IND)
NA ≥4000
≥1.25
T
(IND)
3000
0.94
T
(IND)
NA ≥4000
≥1.25
T
(ADD)
1500
0.47
T
(ADD)
NA
Aq = aqueous extract MIC value; Org = organic extract MIC value; EO = essential oil MIC value; AM = antimicrobial MIC value; Int. = Interaction; NA = no essential oil tested; T = no absolute value could be calculated and therefore only a
tentative interpretation is provided; SYN = synergistic interaction; ADD = additive interaction; IND = indifferent interaction; ANT = antagonistic interaction.
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Table 6.3
MIC (μg/ml) and∑FIC values for the plant: antifungal combinations, against the yeasts.
Combination C. albicans
(ATCC 10231)
C. neoformans
(ATCC 14116)
Aq
AM
∑FIC (Int.) Org
AM
∑FIC (Int.) EO
AM
∑FIC (Int.) Aq
AM
∑FIC (Int.) Org
AM
∑FIC (Int.) EO
AM
∑FIC (Int.)
A. betulina + amphotericin B ≥4000
≥12.50
T
(ANT)
1500
4.69
3.51
(IND)
2000
6.25
5.01
(ANT)
130
0.39
1.04
(IND)
250
0.78
2.33
(IND)
130
0.39
1.17
(IND)
A. betulina + nystatin 380
1.17
0.56
(ADD)
1000
3.13
1.67
(IND)
1000
3.13
1.84
(IND)
380
1.17
0.88
(ADD)
500
1.56
1.67
(IND)
380
1.17
1.26
(IND)
A. ferox + amphotericin B 3000
9.38
T
(ANT)
1500
4.69
3.51
(IND)
NA ≥4000
≥12.50
T
(ANT)
130
0.39
1.02
(IND)
NA
A. ferox + nystatin ≥4000
≥12.50
T
(ANT)
1000
3.13
1.84
(IND)
NA ≥4000
≥12.50
T
(ANT)
250
0.78
0.53
(ADD)
NA
A. afra + amphotericin B 3000
9.38
6.76
(ANT)
2000
6.25
5.34
(ANT)
1500
4.69
4.51
(ANT)
190
0.59
1.69
(IND)
190
0.59
1.75
(IND)
250
0.78
2.33
(IND)
A. afra + nystatin 750
2.35
1.19
(IND)
380
1.17
0.75
(ADD)
1000
3.13
2.34
(IND)
190
0.59
0.57
(ADD)
500
1.56
1.67
(IND)
500
1.56
1.67
(IND)
A. linearis + amphotericin B ≥4000
≥12.50
T
(ANT)
1500
4.69
3.51
(IND)
NA 750
2.35
T
(ANT)
130
0.39
1.09
(IND)
NA
A. linearis + nystatin 1500
4.69
T
(IND)
1000
3.13
1.67
(IND)
NA 1500
4.70
T
(IND)
190
0.59
0.51
(ADD)
NA
L. javanica + amphotericin B 500
1.56
1.67
(IND)
750
2.35
2.25
(IND)
2000
6.25
5.34
(ANT)
130
0.39
1.13
(IND)
190
0.59
2.00
(IND)
100
0.30
1.02
(IND)
L. javanica + nystatin 190
0.59
0.50
(SYN)
380
1.17
0.88
(ADD)
2000
6.25
4.00
(IND)
250
0.78
0.75
(ADD)
190
0.59
0.88
(ADD)
250
0.78
1.16
(IND)
P. sidoides + amphotericin B 750
2.34
2.00
(IND)
1500
4.69
3.76
(IND)
NA 130
0.39
1.13
(IND)
190
0.59
1.63
(IND)
NA
P. sidoides + nystatin 500
1.56
1.00
(ADD)
750
2.35
1.38
(IND)
NA 250
0.78
0.75
(ADD)
190
0.59
0.51
(ADD)
NA
S. frutescens + amphotericin B ≥4000
≥12.50
T
(ANT)
100
0.30
0.22
(SYN)
NA ≥4000
≥12.50
T
(ANT)
750
2.35
6.76
(ANT)
NA
S. frutescens + nystatin ≥4000
≥12.50
T
(ANT)
1000
3.13
1.67
(IND)
NA ≥4000
≥12.50
T
(ANT)
500
1.56
1.50
(IND)
NA
Aq = aqueous extract MIC value; Org = organic extract MIC value; EO = essential oil MIC value; AM = antimicrobial MIC value; Int. = Interaction; NA = no essential oil tested;
T = no absolute value could be calculated and therefore only a tentative interpretation is provided; SYN = synergistic interaction; ADD = additive interaction; IND = indifferent
interaction; ANT = antagonistic interaction.
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Fig. 1. Isobologram for Agathosma betulina ( = aqueous extract; = organic ex-
tract;▲= essential oil) in combinationwith ciproﬂoxacin, when tested at various ra-
tios, against Escherichia coli.
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where itwas found that the plant had the ability to delay the production
of midazolammetabolites, resulting in a 40% reduction in clearance.
Some other Southern African medicinal plants have demonstrated
the potential for interactions with conventional drugs due to their ef-
fects on metabolic enzymes. For example, Hypoxis hemerocallidea
(African potato) has been shown to modulate the CYP3A4 enzyme
(Mills et al., 2005). Fasinu et al. (2013a) found that the aqueous extract
of H. hemerocallidea has the potential to modulate other CYP450 en-
zymes too. Another Southern African medicinal plant showing interac-
tive potential, is Harpagophytum procumbens (devil's claw), which has
been found to have an effect on the CYP3A4 enzyme. Instead of the en-
zyme induction as seen with the previously mentioned examples,
devil's claw inhibits the enzyme, thereby resulting in prolonged activity
of conventional drugs metabolised by this enzyme, which could result
in an increased risk of adverse effects and toxicity. An example is the
combination of devil's claw together withwarfarin, resulting in purpura
(Fugh-Berman, 2000; Van den Bout-Van den Beukel et al., 2006).
Ciproﬂoxacin was one of the antimicrobials most commonly associ-
ated with a positive interactive potential, which was also demonstrated
in this current study. Ahmad and Aqil (2006) tested ciproﬂoxacin in
combination with crude extracts of 15 Indian medicinal plants, where
the combinations showed synergistic effects when tested against enter-
ic bacteria. Van Vuuren et al. (2009) evaluated the interactions between
ciproﬂoxacin and the essential oils of M. alternifolia, T. vulgaris,
M. piperita and R. ofﬁcinalis, using the micro-dilution assay, against var-
ious pathogens. In the study, a varied interactive proﬁlewas seen,which
included synergistic, antagonistic and additive interactions. It was found
that the interactions were very much dependant on the ratios in which
the agents were combined and ultimately dependent on the ﬁnal con-
centrations used. The previous studies show that ciproﬂoxacin:plant
containing combinations mostly demonstrated synergistic proﬁles,which was also noted in this current study, where ciproﬂoxacin was
found to provide the most notable combinations with the selected me-
dicinal plants.4. Conclusions
Themajority of the conventional antimicrobials in combinationwith
commercially relevant medicinal plants used in Southern Africa
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Fig. 2. Isobologram for Artemisia afra ( = aqueous extract; = organic extract; ▲=
essential oil) in combination with ciproﬂoxacin, when tested at various ratios, against
Escherichia coli.
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Fig. 3. Isobologram for Sutherlandia frutescens ( = aqueous extract; = organic ex-
tract) in combination with ciproﬂoxacin, when tested at various ratios, against Escherichia
coli.
196 Z. Hübsch et al. / South African Journal of Botany 93 (2014) 185–197demonstrated indifferent interactive proﬁles (42.44%), followed by ad-
ditive interactions (35.71%); which alleviate some concerns related to
concurrent use of the two forms of healthcare, since these interactions
are not associated with any advantages or disadvantages. Synergy was
seen for 14.29% of the antimicrobial:medicinal plant combinations stud-
ied. The implications of a synergistic interaction include enhanced efﬁ-
cacy, thereby allowing lower dose administration, with reduced side
effects and possibly reduced antimicrobial resistance (Van Vuuren and
Viljoen, 2011). Of the 420 antimicrobial:medicinal plant combinations
tested, 7.56% demonstrated antagonistic interactions. The implications
of an antagonistic interaction include a reduction in the efﬁcacy of con-
ventional antimicrobials, thereby increasing the burden placed on
healthcare systems. Inmost combination studies found in the literature,
synergistic interactions are emphasized, with the reporting of antago-
nism being neglected. In the current study, a few antagonistic interac-
tions were identiﬁed, with the most considerable antagonism seen
with the aqueous extract of A. afra with ciproﬂoxacin against E. coli,which could have an impact on the treatment of gastrointestinal com-
plaints caused by E. coli.
None of the conventional antimicrobials (independently), and none
of the notable combinations investigated demonstrated toxicity in the
BSLA and MTT assays. However, some of the individual plant samples
demonstrated toxicity in the BSLA, with a mortality of 100 ± 0.00%,
70.13 ± 5.29% and 82.69 ± 4.51% for A. betulina (essential oil),
L. javanica (organic extract) and S. frutescens (organic extract), respec-
tively. In the MTT assay, the essential oils of A. betulina and A. afra dem-
onstrated some toxicity, however, this was not considered signiﬁcant
enough to determine IC50 values.
Future recommendations include further in vivo investigations for
the combinations demonstrating notable synergistic or antagonistic in-
teractions, to support the in vitro ﬁndings. In addition, studies to deter-
mine the possible mechanism of action resulting in the observed
interaction are also warranted, as well as the determination of active
compounds within plant material responsible for the interactions.Acknowledgements
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